Specialized Disclosure Report (sd)
2020年8月15日 - 12:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
TEVA
PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
|
|
|
|
|
ISRAEL
|
|
001-16174
|
|
N/A
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
5 Basel Street,
P.O. Box 3190,
Petach
Tikva, Israel 4951033
(Address of principal executive offices)(Zip Code)
Eli Kalif
Executive
Vice President, Chief Financial Officer
Tel: 972-3-914-8171
(Name and telephone number, including area code, of the person to
contact in connection with this report.)
Check the appropriate box to
indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
|
|
|
☒
|
|
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2019.
|
Items
|
1.01 and 1.02 Conflict Minerals Disclosure, Exhibit
|
Conflict Minerals Disclosure and Report
A copy of
the Companys Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at https://www.tevapharm.com/globalassets/tevapharm-vision-files/2019_conflict_minerals_report.pdf
Listed below is the following exhibit filed as part of this report:
Exhibit 1.01 Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly
authorized undersigned.
|
|
|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
|
(Registrant)
|
By
|
|
/s/ Eli Kalif
|
|
|
Eli Kalif
|
|
|
Executive Vice President, Chief Financial Officer
|
August 14, 2020
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024